CUI1 stringlengths 8 8 | RELA stringlengths 3 54 | CUI2 stringlengths 8 8 | Name1 stringlengths 1 2.86k ⌀ | Name2 stringlengths 1 2.86k ⌀ | Def1 stringlengths 1 8.95k ⌀ | Def2 stringlengths 1 8.95k ⌀ |
|---|---|---|---|---|---|---|
C0000289 | mapped_to | C3885972 | 2-Hydroxyphenethylamine | 2-(4-(2-(2-hydroxy-2-phenylethylamino)ethyl)phenoxy)propanoic acid | Simple amine found in the brain. It may be modulator of sympathetic functions. Its derivatives are adrenergic agonists and antagonists. It is also used in chemical industry. | null |
C0000289 | mapped_to | C4276705 | 2-Hydroxyphenethylamine | 2-(4-(nitrophenyl)butan-2-ylamino)-1-(4-methoxyphenyl)ethanol | Simple amine found in the brain. It may be modulator of sympathetic functions. Its derivatives are adrenergic agonists and antagonists. It is also used in chemical industry. | null |
C0000291 | mapped_to | C0214070 | 2-Isopropylmalate Synthase | LEU4 protein, S cerevisiae | An enzyme that catalyzes the first step in the biosynthetic pathway to LEUCINE, forming isopropyl malate from acetyl-CoA and alpha-ketoisovaleric acid. This enzyme was formerly listed as EC 4.1.3.12. | null |
C0000291 | mapped_to | C1959288 | 2-Isopropylmalate Synthase | MAM3 protein, Arabidopsis | An enzyme that catalyzes the first step in the biosynthetic pathway to LEUCINE, forming isopropyl malate from acetyl-CoA and alpha-ketoisovaleric acid. This enzyme was formerly listed as EC 4.1.3.12. | null |
C0000291 | mapped_to | C4277502 | 2-Isopropylmalate Synthase | LEU9 protein, S cerevisiae | An enzyme that catalyzes the first step in the biosynthetic pathway to LEUCINE, forming isopropyl malate from acetyl-CoA and alpha-ketoisovaleric acid. This enzyme was formerly listed as EC 4.1.3.12. | null |
C0000291 | inverse_isa | C0014442 | 2-Isopropylmalate Synthase | Enzymes | An enzyme that catalyzes the first step in the biosynthetic pathway to LEUCINE, forming isopropyl malate from acetyl-CoA and alpha-ketoisovaleric acid. This enzyme was formerly listed as EC 4.1.3.12. | Biological molecules that possess catalytic activity. They may occur naturally or be synthetically created. Enzymes are usually proteins, however CATALYTIC RNA and CATALYTIC DNA molecules have also been identified. |
C0000291 | inverse_isa | C0024188 | 2-Isopropylmalate Synthase | Lyase | An enzyme that catalyzes the first step in the biosynthetic pathway to LEUCINE, forming isopropyl malate from acetyl-CoA and alpha-ketoisovaleric acid. This enzyme was formerly listed as EC 4.1.3.12. | A class of enzymes that catalyze the cleavage of C-C, C-O, and C-N, and other bonds by other means than by hydrolysis or oxidation. (Enzyme Nomenclature, 1992) EC 4. |
C0000291 | inverse_isa | C0033684 | 2-Isopropylmalate Synthase | Proteins | An enzyme that catalyzes the first step in the biosynthetic pathway to LEUCINE, forming isopropyl malate from acetyl-CoA and alpha-ketoisovaleric acid. This enzyme was formerly listed as EC 4.1.3.12. | Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. |
C0000291 | disposition_of | C4521999 | 2-Isopropylmalate Synthase | Lyase (disposition) | An enzyme that catalyzes the first step in the biosynthetic pathway to LEUCINE, forming isopropyl malate from acetyl-CoA and alpha-ketoisovaleric acid. This enzyme was formerly listed as EC 4.1.3.12. | null |
C0000294 | has_ingredient | C0543371 | mesna | mesna 400 MG Oral Tablet | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_ingredient | C0704829 | mesna | mesna 100 MG/ML Injectable Solution | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | inverse_isa | C0033613 | mesna | Protective Agents | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | Synthetic or natural substances which are given to prevent a disease or disorder or are used in the process of treating a disease or injury due to a poisonous agent. |
C0000294 | mapped_to | C0045260 | mesna | 2,2'-dithiodiethanesulfonic acid | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | mapped_to | C0065541 | mesna | MAID protocol | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | A regimen consisting of doxorubicin, ifosfamide, dacarbazine and mesna used to treat unresectable soft tissue sarcoma. |
C0000294 | mapped_to | C0066238 | mesna | methyl coenzyme M | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | mapped_to | C0128528 | mesna | MINE-ESHAP protocol | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | mapped_to | C0165279 | mesna | arginine 2-mercaptoethane sulfonate | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | mapped_to | C0208853 | mesna | VlhP protocol | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | mapped_to | C0295719 | mesna | MINE protocol | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | mapped_to | C0384398 | mesna | MINE-BOP protocol | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | mapped_to | C0385502 | mesna | VIE protocol | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | mapped_to | C0611467 | mesna | acetylcoenzyme M | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | mapped_to | C0613195 | mesna | 2-mercaptoethanesulfonate-cysteine disulfide | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | mapped_to | C0652008 | mesna | IVADIC regimen | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | mapped_to | C0669632 | mesna | MIZE protocol | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | mapped_to | C0756317 | mesna | VIMP protocol | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | mapped_to | C0756999 | mesna | 2-mercaptoethanesulfonic acid albumin | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | mapped_to | C0906409 | mesna | ICE protocol 5 | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | mapped_to | C0909619 | mesna | VACIME protocol | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | mapped_to | C0911798 | mesna | NaPIM protocol | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | mapped_to | C0912225 | mesna | MINT protocol | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | mapped_to | C0912478 | mesna | TIC protocol | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | A regimen consisting of paclitaxel, ifosfamide, mesna and carboplatin used as salvage therapy for the treatment of advanced-stage testicular cancer; also used for the treatment of unresectable and recurrent squamous cell head and neck cancer. |
C0000294 | mapped_to | C1450373 | mesna | 12-aza-13-carboxy-14-hydroxy-11-oxo-3,4-dithiapentadecanesulfonic acid 14-phosphate | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | mapped_to | C4549363 | mesna | homopiperazine-1,4-bis (2-ethanesulfonic acid) | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_ingredient | C0703108 | mesna | mesna intravenous kit | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | contains | C1170010 | mesna | ifosfamide / mesna | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_ingredient | C0713917 | mesna | mesna 100 MG/ML Injectable Solution [Mesnex] | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_ingredient | C0779896 | mesna | {10 (20 ML ifosfamide 50 MG/ML Injection) / 10 (mesna 100 MG/ML Injectable Solution) } Pack | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_ingredient | C0977728 | mesna | {2 (60 ML ifosfamide 50 MG/ML Injection) / 6 (mesna 100 MG/ML Injectable Solution) } Pack | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_ingredient | C1168993 | mesna | Ifex/Mesnex (obsolete), intravenous kit | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_ingredient | C1169827 | mesna | mesna 400 MG Oral Tablet [Mesnex] | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_ingredient | C1877938 | mesna | {2 (Ifosfamide 50 MG/ML Injectable Solution [Ifex]) / 6 (Mesna 100 MG/ML Injectable Solution [Mesnex]) } Pack [Ifex / Mesnex Kit 2/6] | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_ingredient | C2370850 | mesna | Ifex / Mesnex Kit 10 includes Ifex / Mesnex Kit 5/3 | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_ingredient | C2741045 | mesna | {5 (20 ML ifosfamide 50 MG/ML Injection) / 3 (mesna 100 MG/ML Injectable Solution) } Pack | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | use | C0678115 | mesna | Uromitexan | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | use | C0721681 | mesna | Mesnex | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | inverse_isa | C2069109 | mesna | anti-hemorrhagic cystitis agents | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_active_ingredient | C0704829 | mesna | mesna 100 MG/ML Injectable Solution | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_active_ingredient | C0543371 | mesna | mesna 400 MG Oral Tablet | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_active_moiety | C0704829 | mesna | mesna 100 MG/ML Injectable Solution | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_active_ingredient | C0713917 | mesna | mesna 100 MG/ML Injectable Solution [Mesnex] | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_active_ingredient | C1169827 | mesna | mesna 400 MG Oral Tablet [Mesnex] | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_member | C3653482 | mesna | Detoxifying agents for antineoplastic treatment | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_member | C0026698 | mesna | mucolytic agents | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | Any agent that dissolves mucus, making it less thick and sticky. This makes it easier for the mucus to drain from the upper respiratory system, be removed through coughing, or be transported through the gastrointestinal (GI) tract. |
C0000294 | inverse_isa | C0003295 | mesna | Antidote | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | Agents counteracting or neutralizing the action of POISONS. |
C0000294 | inverse_isa | C0301122 | mesna | Organic sulfonic acid | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | inverse_isa | C1320236 | mesna | Allergen class | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | inverse_isa | C1320237 | mesna | Drug allergens | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_active_ingredient | C0543371 | mesna | mesna 400 MG Oral Tablet | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_basis_of_strength_substance | C0543371 | mesna | mesna 400 MG Oral Tablet | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_precise_active_ingredient | C0543371 | mesna | mesna 400 MG Oral Tablet | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_active_ingredient | C0543372 | mesna | mesna 600 MG Oral Tablet | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_basis_of_strength_substance | C0543372 | mesna | mesna 600 MG Oral Tablet | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_precise_active_ingredient | C0543372 | mesna | mesna 600 MG Oral Tablet | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_causative_agent | C0569874 | mesna | Mesna adverse reaction | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_causative_agent | C0571184 | mesna | Allergy to mesna | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_active_ingredient | C0704829 | mesna | mesna 100 MG/ML Injectable Solution | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_basis_of_strength_substance | C0704829 | mesna | mesna 100 MG/ML Injectable Solution | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_precise_active_ingredient | C0704829 | mesna | mesna 100 MG/ML Injectable Solution | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_active_ingredient | C3215349 | mesna | mesna Injectable Product | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_active_ingredient | C3215351 | mesna | mesna Oral Product | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_basis_of_strength_substance | C4709094 | mesna | Mesna 1 g/10 mL solution for injection ampule | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_precise_active_ingredient | C4709094 | mesna | Mesna 1 g/10 mL solution for injection ampule | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_basis_of_strength_substance | C4709095 | mesna | Mesna 400 mg/4 mL solution for injection ampule | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_precise_active_ingredient | C4709095 | mesna | Mesna 400 mg/4 mL solution for injection ampule | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_active_ingredient | C4753961 | mesna | Mesna only product | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_active_ingredient | C4756947 | mesna | Mesna only product in oral dose form | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_active_ingredient | C4756948 | mesna | Mesna only product in parenteral dose form | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_active_ingredient | C5394747 | mesna | Mesna only product in pulmonary dose form | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | has_active_ingredient | C5394748 | mesna | Mesna-containing product in pulmonary dose form | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | isa | C0543371 | mesna | mesna 400 MG Oral Tablet | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | isa | C0543372 | mesna | mesna 600 MG Oral Tablet | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | isa | C0704829 | mesna | mesna 100 MG/ML Injectable Solution | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | isa | C3215349 | mesna | mesna Injectable Product | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | isa | C3215351 | mesna | mesna Oral Product | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | isa | C4753961 | mesna | Mesna only product | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | isa | C5394748 | mesna | Mesna-containing product in pulmonary dose form | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | inverse_isa | C0013227 | mesna | Pharmaceutical Preparations | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form. |
C0000294 | inverse_isa | C0300973 | mesna | Sulfur and/or sulfur compound-containing product | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | inverse_isa | C1268903 | mesna | Cytoprotective agent | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | Agents administered before, with, or after cancer therapy to reduce or prevent damage or toxicity to the normal cells. (NCI) |
C0000294 | active_ingredient_of | C0007974 | mesna | Chelating Agents | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. |
C0000294 | active_ingredient_of | C1268903 | mesna | Cytoprotective agent | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | Agents administered before, with, or after cancer therapy to reduce or prevent damage or toxicity to the normal cells. (NCI) |
C0000294 | parent_of | C2267095 | mesna | M [Preparations] | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | tradename_of | C0721681 | mesna | Mesnex | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | tradename_of | C1330402 | mesna | Mesna Nova Plus | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | null |
C0000294 | may_be_prevented_by | C0010692 | mesna | Cystitis | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain. |
C0000294 | may_be_treated_by | C0010692 | mesna | Cystitis | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain. |
C0000294 | has_contraindicated_drug | C0013182 | mesna | Drug Allergy | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | Immunologically mediated adverse reactions to medicinal substances used legally or illegally. |
C0000294 | may_be_prevented_by | C0013221 | mesna | Drug toxicity | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | An adverse effect of a drug used therapeutically or diagnostically. |
C0000294 | may_be_prevented_by | C0019080 | mesna | Hemorrhage | A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE. | Bleeding or escape of blood from a vessel. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.